Screener
BioCryst Pharmaceuticals BCRX Total Revenue
Total Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales, net | $157,513 | $162,430 | $308,914 | $306,217 |
| License and other revenues | 60,737 | 923 | 65,749 | 2,670 |
| Total revenues | 218,250 | 163,353 | 374,663 | 308,887 |
| Expenses: | ||||
| Cost of product sales | 3,840 | 2,798 | 9,217 | 7,366 |
| Acquired in-process research and development | — | — | 697,761 | — |
| Research and development | 51,969 | 43,386 | 112,288 | 80,656 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's total revenue?
- BioCryst Pharmaceuticals (BCRX) reported total revenue of $218.25M in Q2 2026.
- How has BioCryst Pharmaceuticals's total revenue changed year-over-year?
- BioCryst Pharmaceuticals's total revenue increased by 33.6% year-over-year, from $163.35M to $218.25M.
- What is the long-term trend for BioCryst Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's total revenue has grown at a 53.6% compound annual growth rate (CAGR), from $157.17M to $874.84M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about BioCryst Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude